Zai Lab (ZLAB) Amortization of Deferred Charges (2018 - 2026)
Zai Lab (ZLAB) posted quarterly Amortization of Deferred Charges of -$1.4 million for Q1 2026, down 4.66% year-on-year from -$1.5 million in Q1 2025, and down 3.26% on a QoQ basis from -$1.3 million in Q4 2025.
Zai Lab (ZLAB) Amortization of Deferred Charges (2018 - 2026) Analysis & Trends
Zai Lab (ZLAB) has reported Amortization of Deferred Charges for 9 consecutive years, with -$1.4 million the latest figure, recorded in Q1 2026.
- Quarterly Amortization of Deferred Charges fell 4.66% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.4 million (down 34.68% YoY) and the FY2025 annual result came in at -$5.3 million, down 51.7% from the prior year.
- Amortization of Deferred Charges declined to -$1.4 million in Q1 2026 per ZLAB's latest filing, from -$1.3 million in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for ZLAB reached as high as -$561000.0 in Q4 2022 and fell as low as -$1.4 million in Q1 2026.
- A 5-year average of -$955176.5 and a median of -$839000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges slumped 807.69% — and 2024, when it increased 26.01%.
- Year by year, Amortization of Deferred Charges stood at -$561000.0 in 2022, then tumbled by 49.02% to -$836000.0 in 2023, then slipped by 19.86% to -$1.0 million in 2024, then slumped by 34.63% to -$1.3 million in 2025, then dropped by 3.26% to -$1.4 million in 2026.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered -$1.4 million, -$1.3 million, and -$1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,011.97 Bn | 67,011.68 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.88 Bn | 467.08 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.20 Bn | 114.96 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.17 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | Zai Lab | 20.57 Bn | 19.82 Bn | 61.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.39 Mn |
| Mar 31, 2026 | -1.39 Mn |
| Dec 31, 2025 | -1.35 Mn |
| Dec 31, 2025 | -1.35 Mn |
| Sep 30, 2025 | -1.33 Mn |
| Sep 30, 2025 | -1.33 Mn |
| Jun 30, 2025 | -1.33 Mn |
| Jun 30, 2025 | -1.33 Mn |
| Mar 31, 2025 | -1.33 Mn |
| Mar 31, 2025 | -1.33 Mn |
| Dec 31, 2024 | -1.00 Mn |
| Dec 31, 2024 | -1.00 Mn |
| Sep 30, 2024 | -839,000.00 |
| Sep 30, 2024 | -839,000.00 |
| Jun 30, 2024 | -839,000.00 |
| Jun 30, 2024 | -839,000.00 |
| Mar 31, 2024 | -840,000.00 |
| Mar 31, 2024 | -840,000.00 |
| Dec 31, 2023 | -836,000.00 |
| Dec 31, 2023 | -836,000.00 |